High compliance with Optune linked to greatest survival benefit for glioblastoma There is a dose response curve. (Which also should convince the naysayers that the device is effective) The better the compliance, the better the patients do. They have been saying 75% is the target compliance rate but the new data shows that 90% should be the target. Those patients who had a compliance rate of 90% or more, had a survival rate of 29.3% at 5 years, compared to the control group (temodar) which had a 4.5% survival rate, an almost 650% increase in survival rate.
With a compliance of 70-80%, the 5 year survival rate drops to 19.9%. Still much better than the control group... so don't stress too much if you can't hit the 90%, but try.
Lomustine and Bevacizumab in Progressive Glioblastoma. These results were disappointing. Last year, the data was presented that this combination worked very well. This year they are saying that although there is a a relatively large improvement in progression free survival (from 1.5 months with the Lomustine (CCNU) alone to 4.2 months with the combination of Lomustine and Bevacizumab (Avastin), there was little (less than a month) improvement in overall survival.
Medicenna Presents Updates on Phase 2b Clinical Trial of MDNA55 at the Annual Meeting of the Society of Neuro-Oncology This shows that the convection enhanced delivery methods have improved to the point where they can get the drug, on average, to over 75% of the tumor, and it should only get better with more experience. They compare this to the PRECISE trial where the drug only got to about 20% of the tumor.
Here is a link to the poster.
There is a phase 2 clinical trial going on now for this treatment, MDNA55, in patients with recurrent or progressive GBM.
Disclaimer: Medicenna Therapeutics is a sponsor of the Musella Foundation
Effectiveness of ONC201 in H3 K27M Glioma to be Presented at SNO This H3 K27M mutation is a marker for the worst prognostic group of brain tumors, and as far as I know, this is the first drug in clinical trials to target this mutation. Aside from being present in some of the worst GBMs, it is present in most DIPG tumors.
